Quick-Med Technologies Inc announced the development of a proprietary Stay Fresh technology and that the Company is seeking partners to commercialize this revolutionary new technology in key segments of the textile market. Stay Fresh greatly surpasses the performance of currently available freshness-enhancing textiles technologies.
It is highly effective in controlling the growth of odor-causing bacteria and preventing associated staining. Stay Fresh technology is also extremely durable, effective for the life of the treated fabric by maintaining sustained efficacy through 75 laundering cycles, thus overcoming a major shortcoming common among today’s leading antimicrobial technologies.
“Stay Fresh is a very exciting addition to our Company’s technology portfolio,” said J. Ladd Greeno, CEO of Quick-Med Technologies. “We believe that the unprecedented sustained performance of Stay Fresh will provide apparel and other textile manufacturers an important new way to differentiate and add value to their products.”
Stay Fresh technology has been designed to cost-effectively enhance a wide variety of textile applications including essential apparel, work wear, active wear, bedding and health care textiles.
With the basic technology development complete, the Company will now focus on identifying commercialization partners with the interest and resources to bring this technology to key market segments. Quick-Med has initiated EPA registration which, when achieved, will allow its customers to make “treated article” claims and market the antimicrobial features of Stay Fresh technology. Additionally, the Company plans to pursue FDA clearance for select medical textile applications.
“Stay Fresh will provide efficacy and durability that is far superior to any other product on the market at a very attractive cost,” said Dr. Jerry Olderman, VP of Research & Development at Quick-Med. “Our research team has developed a high performance textile treatment that overcomes the key shortcomings of currently available technologies.”
Stay Fresh can be used with a broad range of fiber types and blends on whites and colored fabrics. The patent-pending technology employs a safe, eco-friendly active agent that remains in full concentration on any of several fabric types and compositions. It controls a broad range of both Gram-positive and Gram negative bacteria throughout the life of the product. Stay Fresh finish is not depleted during repeated laundering in hot or cold water. This extraordinary durability protects against the development of resistance by bacteria and the sustained bond means that there’s no environmental impact of the wash water.
Stay Fresh is Quick-Med’s newest platform technology. It joins NIMBUS, a non-leaching antimicrobial technology recently cleared by FDA and is initially being commercialized in wound care products; NimbuDerm; a novel skin-sanitizer technology that provides comfortable, ongoing protection for 6 or more hours; and MultiStat, a family of patented compounds that have been shown to have significant benefit in promoting the maintenance, healing and repair of skin and eye tissue.
Quick-Med Technologies, Inc. is a life sciences company that is developing innovative technologies for the healthcare and consumer markets.
It is highly effective in controlling the growth of odor-causing bacteria and preventing associated staining. Stay Fresh technology is also extremely durable, effective for the life of the treated fabric by maintaining sustained efficacy through 75 laundering cycles, thus overcoming a major shortcoming common among today’s leading antimicrobial technologies.
“Stay Fresh is a very exciting addition to our Company’s technology portfolio,” said J. Ladd Greeno, CEO of Quick-Med Technologies. “We believe that the unprecedented sustained performance of Stay Fresh will provide apparel and other textile manufacturers an important new way to differentiate and add value to their products.”
Stay Fresh technology has been designed to cost-effectively enhance a wide variety of textile applications including essential apparel, work wear, active wear, bedding and health care textiles.
With the basic technology development complete, the Company will now focus on identifying commercialization partners with the interest and resources to bring this technology to key market segments. Quick-Med has initiated EPA registration which, when achieved, will allow its customers to make “treated article” claims and market the antimicrobial features of Stay Fresh technology. Additionally, the Company plans to pursue FDA clearance for select medical textile applications.
“Stay Fresh will provide efficacy and durability that is far superior to any other product on the market at a very attractive cost,” said Dr. Jerry Olderman, VP of Research & Development at Quick-Med. “Our research team has developed a high performance textile treatment that overcomes the key shortcomings of currently available technologies.”
Stay Fresh can be used with a broad range of fiber types and blends on whites and colored fabrics. The patent-pending technology employs a safe, eco-friendly active agent that remains in full concentration on any of several fabric types and compositions. It controls a broad range of both Gram-positive and Gram negative bacteria throughout the life of the product. Stay Fresh finish is not depleted during repeated laundering in hot or cold water. This extraordinary durability protects against the development of resistance by bacteria and the sustained bond means that there’s no environmental impact of the wash water.
Stay Fresh is Quick-Med’s newest platform technology. It joins NIMBUS, a non-leaching antimicrobial technology recently cleared by FDA and is initially being commercialized in wound care products; NimbuDerm; a novel skin-sanitizer technology that provides comfortable, ongoing protection for 6 or more hours; and MultiStat, a family of patented compounds that have been shown to have significant benefit in promoting the maintenance, healing and repair of skin and eye tissue.
Quick-Med Technologies, Inc. is a life sciences company that is developing innovative technologies for the healthcare and consumer markets.
